Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2021


NGM Biopharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)


333 Oyster Point Boulevard

South San Francisco, California



(Address of Principal Executive Offices)


(Zip Code)

(650) 243-5555

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange on which registered

Common Stock, par value $0.001 per share




The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 1.01.

Entry into a Material Definitive Agreement.

As previously reported, NGM Biopharmaceuticals, Inc. (“NGM” or the “Company”) entered into that certain Research Collaboration, Product Development and License Agreement, dated as of February 18, 2015 and as subsequently amended (the “Collaboration Agreement”), with Merck Sharp & Dohme Corp. (“Merck”).  Under the terms of the Collaboration Agreement, Merck was required to notify NGM no later than March 17, 2021 of its unilateral decision whether to exercise its option to extend the research and early development program under the collaboration, referred to as the research phase of the collaboration, for an additional two-year term through March 16, 2024. In March 2021, Merck initiated discussions with NGM with respect to elements of the ongoing collaboration that might be optimized to better address the evolving interests and priorities of both NGM and Merck during the remainder of the current research phase through March 16, 2022 and during any extension of the current research phase and any resulting “tail period” of up to three years (as provided for under the Collaboration Agreement). In this regard, the parties are negotiating in good faith certain modifications to the terms of the Collaboration Agreement. In order to allow such negotiations to proceed, Merck and NGM entered into a letter agreement, dated as of March 12, 2021 (the “Letter Agreement”), pursuant to which Merck and NGM have agreed to extend the March 17, 2021 deadline for Merck to deliver its research phase extension notification decision until June 30, 2021. Refer to NGM’s annual report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 15, 2021 (the “2020 10-K”), for additional information regarding NGM’s collaboration with Merck.  

Forward-Looking Statements

Statements contained in this current report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “might,” “any,” “expect” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the Company and Merck potentially reaching agreement on the terms of a modified collaboration; any extension of the research phase of the collaboration; and other statements that are not historical fact. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this current report on Form 8-K. These forward-looking statements are subject to risks and uncertainties, including, without limitation, the risks that Merck may elect not to extend the research phase of the collaboration and the Company may otherwise be unable to reach agreement with Merck on the terms of a modified collaboration and, regardless of whether the Company and Merck reach agreement on the terms of a modified collaboration, the Company expects that Merck will not provide research funding for certain of NGM’s product candidates and the Company’s collaboration with Merck involves numerous other risks, any of which could materially and adversely affect the Company’s business and financial condition; the sufficiency of the Company’s cash resources and need for additional capital; and other risks and uncertainties affecting the Company, its development programs and its collaboration with Merck, including those discussed in the section titled “Risk Factors” in the 2020 10-K and future filings and reports that the Company makes from time to time with the SEC. Except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.


Item 9.01

Financial Statements and Exhibits.








Exhibit No.







Letter Agreement, dated as of March 12, 2021, by and between Merck Sharp & Dohme Corp. and NGM Biopharmaceuticals, Inc.



Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.













NGM Biopharmaceuticals, Inc.





Dated: March 15, 2021






/s/ Siobhan Nolan Mangini







Siobhan Nolan Mangini







Chief Financial Officer



Exhibit 10.1

126 E Lincoln Ave.

Rahway, NJ  07065 U.S.A.







March 12, 2021


NGM Biopharmaceuticals, Inc.

333 Oyster Point Blvd.

South San Francisco, CA 94080

Attention: Chief Executive Officer

Facsimile: 650-583-1646


Cooley LLP

3175 Hanover St.

Palo Alto, CA 94304

Attention: Marya Postner

Facsimile: 650-583-1646


Re:  Research Collaboration, Product Development and License Agreement, dated as of February 18, 2015


Dear David:


Merck Sharp & Dohme Corp. (“Merck”) and NGM Biopharmaceuticals, Inc. (“NGM” and, together with Merck, referred to as the “Parties”) are parties to that certain Research Collaboration, Product Development and License Agreement, dated as of February 18, 2015 (as amended by the First Amendment to Research Collaboration, Product Development and License Agreement entered into by the Parties effective as of January 1, 2016, the letter agreement entered into by the Parties dated March 15, 2019 and the letter agreement entered into by the Parties dated October 2, 2019, collectively, the “Agreement”).  Any capitalized terms used in this letter and not defined herein shall have the meanings ascribed to them in the Agreement.


Merck and NGM intend to continue to collaborate closely and are currently negotiating in good faith an amendment to certain terms of the Agreement to optimize for the interests of both Merck and NGM.  As a result, NGM and Merck agree to extend the deadline set forth in Section 4.1.3 of the Agreement for Merck to deliver its extension notification decision from March 17, 2021 to June 30, 2021 (the “Extended Deadline”).  Following the date of this letter the Parties agree to negotiate mutually acceptable terms for such amendment to the Agreement, or a new agreement, in good faith; provided, however, that neither Party will have any obligation to agree upon the details of or execute any such amendment or agreement. Unless and until amended by the Parties in accordance with Section 16.8 of the Agreement, the remaining terms of the Agreement remain in full force and effect.  




This letter shall be governed by and construed in accordance with the laws of the State of New York without reference to any rules of conflicts of laws.  NGM is required to make public disclosure of the terms of this letter and has provided Merck with a copy of the proposed disclosure, which Merck has reviewed and approves.


The Parties have enjoyed the opportunity to work together under the Agreement and look forward to our continued interactions.  Please countersign below to indicate that NGM is in agreement with the terms of this letter.


















/s/ Benjamin Thorner







Benjamin Thorner







Senior Vice President and Head







Of Business Development & Licensing














NGM Biopharmaceuticals, Inc.



By: /s/ David J. Woodhouse





Name: David J. Woodhouse, Ph.D.




Title: Chief Executive Officer